We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04441918
Recruitment Status : Unknown
Verified June 2020 by Shanghai Junshi Bioscience Co., Ltd..
Recruitment status was:  Recruiting
First Posted : June 22, 2020
Last Update Posted : June 22, 2020
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

Brief Summary:
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal antibody)

Condition or disease Intervention/treatment Phase
COVID-19; and High Infection Risk of SARS-CoV-2 Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose
Actual Study Start Date : June 5, 2020
Estimated Primary Completion Date : December 11, 2020
Estimated Study Completion Date : December 11, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Test group Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody)
JS016 (anti-SARS-CoV-2 monoclonal antibody)

Experimental: Control group Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody)
JS016 (anti-SARS-CoV-2 monoclonal antibody)

Primary Outcome Measures :
  1. Correlation of adverse events with the investigational product [ Time Frame: 12 Weeks ]
    Any adverse event, serious adverse event (SAE) occurred during the clinical study, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs will be observed for all the subjects, the their clinical manifestations and features, severity, time to onset, end time, therapeutic measures and outcomes will be recorded, and the correlation of the adverse events with the investigational product will be judged

Secondary Outcome Measures :
  1. Primary pharmacokinetic variables [ Time Frame: 12 Weeks ]
    Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-last);

  2. Primary pharmacokinetic variables [ Time Frame: 12 Weeks ]
    Maximum concentration (Cmax);

  3. Primary pharmacokinetic variables [ Time Frame: 12 Weeks ]
    Mean residence time (MRT)

  4. Primary pharmacokinetic variables [ Time Frame: 12 Weeks ]
    Terminal half life (t1/2);

Other Outcome Measures:
  1. pharmacokinetic [ Time Frame: 12 Weeks ]
    Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC0-∞);

  2. pharmacokinetic [ Time Frame: 12 Weeks ]
    Time to maximum concentration (Tmax);

  3. pharmacokinetic [ Time Frame: 12 Weeks ]
    Clearance (CL);

  4. pharmacokinetic [ Time Frame: 12 Weeks ]
    Apparent terminal elimination rate constant (λz)

  5. pharmacokinetic [ Time Frame: 12 Weeks ]
    Apparent volume of distribution (Vd)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male and female subjects aged 18 to 45 years, inclusive;
  2. The body weight no less than 50 kg for male subjects and no less than 45 kg for female subjects. Body mass index (BMI) = weight (kg)/square of height (m2), ranging from 18-28 kg/m2 (including the critical value);
  3. Normal or abnormal but clinically insignificant physical examination, vital signs, laboratory tests and other accessory examinations (chest radiology, abdominal B-mode ultrasonography, ECG, etc.);
  4. No plan of pregnancy and being willing to use effective contraceptive measures for subject (including partner) from informed consent to 6 months after administration of investigational product, see Appendix 5 for the specific contraceptive measures;
  5. The subjects are able to understand the content of the study and voluntary to sign the informed consent form; meanwhile, being able to complete the study as required in the protocol.

Exclusion Criteria:

Excluded for novel coronavirus (SARS-CoV-2) infection

  1. Having one of the following evidence on SARS-CoV-2 infection:

    1. SARS-CoV-2 determined by reverse transcription-polymerase chain reaction (RT-PCR) and/or next generation sequencing (NGS) in diagnostic specimens (nasopharyngeal swabs) during screening and pre-randomization (results within 3 days before randomization are accepted);
    2. Previous viral gene sequencing showed high homology with the known SARS-CoV-2;
    3. Positive specific antibody IgM or IgG against serum SARS-CoV-2; Excluded for previous and concomitant medications
  2. Previous vaccination of SARS-CoV-2 vaccine or having participated in the clinical trial on SARS-CoV-2 neutralizing antibody;
  3. Use of therapeutic biologics within 12 weeks prior to screening, or remaining in the elimination period of the drug (within 5 half-lives) at random administration, whichever is longer;
  4. Participation in any other clinical study with intervention of investigational product within 4 weeks prior to screening, or remaining in the elimination period of the drug (within 5 half-lives) prior to screening, whichever is longer;
  5. Vaccination of vaccine within 12 weeks prior to screening, or plan to use Bacille Calmette-Guérin vaccine or other vaccine during the study and within 12 weeks after the study;
  6. Use of hydroxychloroquine, herbal medicine, any prescription drug or over-the-counter drug within (inclusive) 14 days prior to screening; Surgery
  7. Any major surgery within 8 weeks (inclusive) prior to screening, or requiring such surgery during the study, and such surgery is considered by the investigator to possibly bring unacceptable risk for subjects upon confirmation with the sponsor; Abnormal physical examination, laboratory examination and history
  8. Lying systolic blood pressure (SBP) > 140 mmHg or < 90 mmHg, and/or diastolic blood pressure (DBP) > 90 mmHg or < 50 mmHg at screening and randomization;
  9. Total white blood cell (WBC) count < 3.5 x 109/L, platelet < 140 x 109/L, neutrophil < 2.0 x 109/L, or hemoglobin decreased (male < 135 g/L, female < 120 g/L), lymphocytes < 1.0 x 109/L at screening;
  10. ALT or AST > 2 × upper limit of normal, or eGFR ≤ 90 mL/min/1.73m2 at screening;
  11. Abnormal ECG at screening, single QTcF > 450 msec, and/or other abnormalities of clinical significance, unacceptable risk that may be brought by participation in the study;
  12. History of HIV infection, and/or positive aiti-HIV antibody, positive hepatitis B surface antigen (HBsAg), positive hepatitis C antibody (anti-HCV), or positivetreponema pallidum particle agglutination test (TPPA) at screening;
  13. History of transplantation of vital organs (e.g., heart, lung, liver, kidney, etc.);
  14. Having malignant tumor (excluding the malignant tumor cured with no recurrence in the past 5 years, completely resected basal cell and squamous cell carcinoma of skin, completely resected carcinoma in situ of any type);
  15. Other major diseases within one year;
  16. Medical history and previous history suggest the following diseases: including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immune, mental or cerebro- and cardiovascular diseases; Substance abuse, alcohol abuse
  17. History of drug abuse or use of narcotics in the past 5 years, or positive urine drug screening;
  18. History of alcohol abuse or intake of excessive alcohol in the past 6 months (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL liquor, or 100 mL wine), or alcohol test positive; History of allergies
  19. Known serious allergic reaction or hypersensitive to food, inhaled and contact material as well as drugs, or allergic constitution (allergy to various drugs and food);
  20. Known history of allergy or hypersensitivity to the investigational drug, other monoclonal antibody drugs and therapeutic protein preparations (fresh or frozen plasma, human serum albumin, cytokine, interleukin etc.); Pregnancy, lactation
  21. Positive β-Human Chorionic Gonadotropin (β-HCG) or breastfeeding female subjects; Blood loss and others
  22. Subjects who lost blood or donated more than 400 mL, or received blood transfusion in the past 3 months; or plan to donate blood during the study;
  23. Any other condition that the subject is considered by the investigator as inappropriate to participate in the study, for example, potential compliance issue, inability to complete all the tests and evaluations according to the requirements in the protocol, or uncontrolled mental, neurological or psychological disorders, participation in the study is judged by the investigator to be associated with uncontrollable risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04441918

Layout table for location contacts
Contact: Jing Zhang 021-52888189 13816357098@163.com
Contact: Wenhong Zhang 021-52888123 zhangwenhong@fudan.edu.cn

Layout table for location information
Huashan Hospital affiliated to Fudan University Recruiting
Shanghai, China
Contact: Jing Zhang    02152888189 ext 02152888189    13816357098@163.com   
Contact: Wenhong Zhang    02152888123 ext 02152888123    zhangwenhong@fudan.edu.cn   
Sponsors and Collaborators
Shanghai Junshi Bioscience Co., Ltd.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Shanghai Junshi Bioscience Co., Ltd.
ClinicalTrials.gov Identifier: NCT04441918    
Other Study ID Numbers: JS016-001-I
First Posted: June 22, 2020    Key Record Dates
Last Update Posted: June 22, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs